Table 4.
Multivariate Analysis for EFS
Parameter | Mutltivariate | ||
---|---|---|---|
HR | 95% CI | p | |
A. CBF AML | |||
FLT3 (continuous variable) | 1.28 | 0.04–37.78 | 0.88 |
PS | 1.77 | 1.07, 2.91 | 0.03 |
B. NK-AML (FLT3-ITD and wt-FLT3) | |||
Age | 1.02 | 1.01–1.03 | 0.005 |
Race (White vs Non-White) | 0.56 | 0.39–0.81 | 0.002 |
Creatinine | 1.39 | 1.09–1.77 | 0.007 |
FLT3-ITD (continuous variable) | 3.10 | 1.09–8.78 | 0.03 |
Treatment (Ara-C vs. No-Ara-C) | 1.65 | 1.05–2.59 | 0.03 |
Interaction Term | |||
• FLT3-ITD*Treatment | 0.66 | 0.30–1.47 | 0.31 |
C. NK-AML (FLT3-TKD and wt-FLT3) | |||
Age | 1.03 | 1.01–1.04 | 0.0001 |
Race (White vs. Non-White) | 0.47 | 0.30–0.73 | 0.001 |
Creatinine | 1.47 | 1.03–2.09 | 0.003 |
Prior Chemotherapy/XRT | 1.98 | 1.22–3.22 | 0.005 |
FLT3-TKD (continous variable) | 0.57 | 0.11–2.76 | 0.48 |
Treatment (Ara-C vs. No Ara-C) | 0.74 | 0.45–1.23 | 0.25 |
Interaction Term | |||
• FLT3-TKD*Treatment | 0.88 | 0.32–2.46 | 0.81 |
D. Poor Risk AML | |||
Age | 1.02 | 1.01–1.04 | 0.01 |
FLT3 (continuous variable) | 4.24 | 0.15–117.87 | 0.39 |
Treatment (Ara-C vs. No Ara-C) | 1.26 | 0.77–2.04 | 0.35 |
Interaction Term | |||
• FLT3 Mut*Treatment | 0.52 | 0.07–3.79 | 0.52 |